These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 18991714)

  • 1. Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities.
    Mishani E; Abourbeh G; Eiblmaier M; Anderson CJ
    Curr Pharm Des; 2008; 14(28):2983-98. PubMed ID: 18991714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Some implications of receptor kinase signaling pathway for development of multitargeted kinase inhibitors.
    Mitrasinovic PM
    Curr Radiopharm; 2013 Mar; 6(1):48-55. PubMed ID: 23278847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor as a therapeutic target in glioblastoma.
    Kalman B; Szep E; Garzuly F; Post DE
    Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for molecular imaging of epidermal growth factor receptor tyrosine kinase in cancer.
    Mishani E; Hagooly A
    J Nucl Med; 2009 Aug; 50(8):1199-202. PubMed ID: 19617320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
    Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK
    Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors.
    Ping Li W; Meyer LA; Capretto DA; Sherman CD; Anderson CJ
    Cancer Biother Radiopharm; 2008 Apr; 23(2):158-71. PubMed ID: 18454685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.
    Wykosky J; Fenton T; Furnari F; Cavenee WK
    Chin J Cancer; 2011 Jan; 30(1):5-12. PubMed ID: 21192840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models.
    Niu G; Li Z; Xie J; Le QT; Chen X
    J Nucl Med; 2009 Jul; 50(7):1116-23. PubMed ID: 19525473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody.
    Cai W; Chen K; He L; Cao Q; Koong A; Chen X
    Eur J Nucl Med Mol Imaging; 2007 Jun; 34(6):850-8. PubMed ID: 17262214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
    Burtness B
    Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why the epidermal growth factor receptor? The rationale for cancer therapy.
    Baselga J
    Oncologist; 2002; 7 Suppl 4():2-8. PubMed ID: 12202782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer.
    Manning HC; Merchant NB; Foutch AC; Virostko JM; Wyatt SK; Shah C; McKinley ET; Xie J; Mutic NJ; Washington MK; LaFleur B; Tantawy MN; Peterson TE; Ansari MS; Baldwin RM; Rothenberg ML; Bornhop DJ; Gore JC; Coffey RJ
    Clin Cancer Res; 2008 Nov; 14(22):7413-22. PubMed ID: 19010858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC.
    Ghiso E; Migliore C; Ciciriello V; Morando E; Petrelli A; Corso S; De Luca E; Gatti G; Volante M; Giordano S
    Neoplasia; 2017 Dec; 19(12):1012-1021. PubMed ID: 29136529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
    Roberts PJ; Stinchcombe TE; Der CJ; Socinski MA
    J Clin Oncol; 2010 Nov; 28(31):4769-77. PubMed ID: 20921461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies.
    Nedaeinia R; Avan A; Manian M; Salehi R; Ghayour-Mobarhan M
    Curr Drug Targets; 2014; 15(14):1293-301. PubMed ID: 25429712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.